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Associations of height, leg length, and lung function with
cardiovascular risk factors in the Midspan Family Study
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Background: Taller people and those with better lung function are at reduced risk of coronary heart
disease (CHD). Biological mechanisms for these associations are not well understood, but both meas-
ures may be markers for early life exposures. Some studies have shown that leg length, an indicator of
pre-pubertal nutritional status, is the component of height most strongly associated with CHD risk. Other
studies show that height-CHD associations are greatly attenuated when lung function is controlled for.
This study examines (1) the association of height and the components of height (leg length and trunk
length) with CHD risk factors and (2) the relative strength of the association of height and forced
expiratory volume in one second (FEV1) with risk factors for CHD.
Subjects and methods: Cross sectional analysis of data collected at detailed cardiovascular screen-
ing examinations of 1040 men and 1298 women aged 30–59 whose parents were screened in
1972–76. Subjects come from 1477 families and are members of the Midspan Family Study.
Setting: The towns of Renfrew and Paisley in the West of Scotland.
Results: Taller subjects and those with better lung function had more favourable cardiovascular risk
factor profiles, associations were strongest in relation to FEV1. Higher FEV1 was associated with lower
blood pressure, cholesterol, glucose, fibrinogen, white blood cell count, and body mass index. Similar,
but generally weaker, associations were seen with height. These associations were not attenuated in
models controlling for parental height. Longer leg length, but not trunk length, was associated with
lower systolic and diastolic blood pressure. Longer leg length was also associated with more favour-
able levels of cholesterol and body mass index than trunk length.
Conclusions: These findings provide indirect evidence that measures of lung development and
pre-pubertal growth act as biomarkers for childhood exposures that may modify an individual’s risk of
developing CHD. Genetic influences do not seem to underlie height-CHD associations.
Associations between height and coronary heart disease(CHD) have been found in a number of prospectivestudies1–6—CHDmortality decreases with increasing stat-
ure. This finding generally persists after adjustment for possible
confounding factors, such as social class and smoking. There are
a number of possible explanations for these associations. Firstly,
as well as being under genetic control, height is a marker for
exposures influencing childhood growth—such as diet, infec-
tion, or psychological stress—which may themselves be impor-
tant in the aetiology of CHD.7 Secondly, coronary vessel diameter
increases with height and this in turn may be associated with a
decreased risk of luminal occlusion.8 Thirdly, loss of stature
(“shrinkage”) may occur in the early stages of disease and thus
height-disease associations may in part reflect the presence of
pre-existing ill health.6 Fourthly, genes influencing height may
be closely linked to those affecting CHD risk. Finally, the growth
hormone (GH) insulin-like growth factor (IGF) axis may be
important. This axis influences childhood growth and is also
thought to play a part in cardiovascular physiology as suggested
by the observation that adults with hypopituitarism are at
increased risk of CHD and have adverse cardiovascular risk
profiles.9 10
A recent refinement to analyses of the link between height
and CHD has been to investigate associations of the
components of height—leg length and trunk length—with
disease risk. Leg length is a marker of environmental
influences on childhood growth before puberty as, up until
puberty, height increases are in greater part attributable to leg
growth.11 12 Furthermore, secular increases in height, repre-
senting improvements in the nutritional status of populations,
appear to arise more from increases in leg length, rather than
trunk growth.13 14 It is therefore of interest that in analyses of
two cohorts—the Boyd Orr and the Caerphilly studies—
associations between height and CHD risk are found in
relation to leg length but not trunk length.15 7 In the Caerphilly
study short leg length was also associated with insulin
resistance.15 This seems to support the notion that exposures
operating during childhood that influence growth are impor-
tant in the aetiology of CHD.
There is debate concerning the extent to which the
association between height and CHDmortality is attributable to
height related differences in lung function. Adjustment for
forced expiratory volume in one second (FEV1) attenuates
2 5 16
height-CHD associations. Furthermore, in a case-control analy-
sis of the relation between height and CHD, where cases and
controls werematched for FEV1,no height-mortality association
was found.17 It is possible that both height and lung function are
biomarkers for exposures in childhood that influence growth,
lung development, and later heart disease risk.17
Based on the detailed cardiovascular screening examinations
of 2338 adults aged 30–59, this paper investigates the
associations of height, leg length, trunk length, and lung func-
tion with cardiovascular risk factors. As the parents of the study
children had themselves been examined 20 years earlier, we
were also able to assess the extent to whether genetic influences
on stature—as indexed by parental height—underlie associa-
tions between anthropometry and CHD risk factors.
METHODS
The subjects upon whom this research is based were offspring
of 4064 married couples who were screened in the Renfrew-
Paisley (Midspan) Study in 1972–76.18 19 In 1993–4, attempts
were made to trace offspring either through direct contact
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with the original study couple or, where both husband and
wife were dead, through contacts with informants mentioned
on their death certificate. Altogether 4829 offspring aged
30–59 were identified from 2365 couples with children; 3202
of these offspring lived within 45 minutes of Paisley and Ren-
frew. Of these, 1040 men and 1298 women from 1477 families
completed a questionnaire and examination in 1996—a
response rate of 73%. The study protocol was approved by the
relevant research ethics committees.
Survey methods
Information on subjects’ personal and family medical history,
sociodemographic information, and smoking habits was
obtained from detailed self completed questionnaires. Social
class for women was based on their own, rather than their
partner’s, occupation. Examinations were carried out in clinics
staffed by six research nurses who rotated between measure-
ment stations. Measurements included: 12 lead ECG; blood
pressure—recorded using a Dinamapp 8100, three readings
were taken from the left arm with the subject seated and
allowed to rest for five minutes—the mean of the last two
reading for systolic and diastolic blood pressure was used;
non-fasting venous blood samples were analysed for total and
HDL cholesterol, fibrinogen,20 white blood count and glucose;
FEV1 and FVC were measured using a Vitalograph Spirotrac
III.21 Standing height and sitting height were measured with-
out shoes in the Frankfort plane to the nearest millimetre
using a Holtain stadiometer. Leg length was calculated as the
difference between standing height and sitting height, plus
the height of the stool. Weight was measured to the nearest
100 g with Seca digital scales in stockinged feet wearing
indoor clothes. Recorded birthweight data were retrieved from
birth archives for 677 (29%) study members.
Parents were examined between 1972–76 when height was
measured to the nearest centimetre. We calculated mid-
parental height as the average of mother’s and father’s height
for each subject. Father’s social class was determined from
information given on regular occupation and classified
according to the registrar general’s classification. For retired
men the last full time occupation was used. Occupational
social class was classified as non-manual (social class I-III
non-manual) and manual (III manual-V).
Statistical methods
All statistical analyses were performed using Stata version
6.0.22 Least squares regression was used to calculate age
adjusted changes in continuous cardiovascular risk factor levels
associated with a one standard deviation increase in subject’s
height, leg length, trunk length, leg:trunk ratio, and FEV1. Like-
wise logistic regression was used to assess associations with
dichotomous risk factors such as smoking and social class. All
confidence intervals and p values were based on Huber White
robust estimates of variance that accounted for intrafamilial
clustering (P Huber, Proceedings of the Fifth Berkley Sympo-
sium on Mathematical Statistics and probability 1967).
We assessed the effects on FEV1 risk factor associations of
controlling for physical activity, measured by two questions in
a self report questionnaire. The questions assessed levels of
activity (a) during day to day activity and (b) during leisure
time on 4 point scales.
RESULTS
Table 1 presents summary statistics for the cardiovascular risk
factors examined. For most of the variables complete data
were available for most subjects. The exceptions were recorded
birth weight (available for 29% of subjects), HDL cholesterol
(84%), and white cell count (89%). The social class distribu-
tion of survey members was slightly skewed towards the
upper social classes because eligibility required that (a) the
subject’s parents had participated in 1972–76, (b) their
parents were alive and traceable in 1993–4 (or traceable via the
death certificate informant), and (c) the subjects themselves
had agreed to take part in the study and non-response at each
of the stages is likely to be socially patterned. Furthermore, in
women, social class was based on their own occupations and
many were in clerical employment.
Table 1 Distribution of cardiovascular risk factors for the male and female study
members





Mean (SD) Mean (SD)
Age at interview (y) (1040/1298) 44.87 (6.26) 45.23 (6.14)
Systolic blood pressure (mm Hg) (1035/1278) 131.27 (15.27) 123.81 (15.63)
Diastolic blood pressure (mm Hg) (1035/1278) 79.17 (10.92) 70.86 (10.00)
Total cholesterol (mmol/l) (1015/1249) 5.39 (0.97) 5.16 (0.95)
High density lipoprotein cholesterol (mmol/l) (820/1146) 1.30 (0.33) 1.50 (0.36)
Random glucose (mmol/l) (1017/1252) 5.60 (1.94) 5.15 (1.16)
Fibrinogen (g/l) (1008/1236) 3.07 (0.75) 3.24 (0.75)
White blood cell count (109/l) (934/1149) 6.12 (1.73) 6.32 (1.80)
Forced expiratory volume in 1 second (l) (1009/1248) 3.66 (0.64) 2.63 (0.46)
Forced vital capacity (l) (980/1215) 4.81 (0.76) 3.42 (0.55)
Recorded birth weight (kg) (293/384) 3.41 (0.51) 3.32 (0.53)
Body mass index (kg/m2) (1040/1281) 26.52 (4.01) 25.88 (4.95)
Height (cm) (1040/1297) 175.01 (6.50) 161.27 (5.87)
Trunk length (cm) (1037/1293) 93.37 (3.60) 87.00 (3.19)
Leg length (cm) (1037/1293) 81.63 (4.25) 74.26 (3.83)
n (%) n (%)
Cigarette smoking status
Never smoked 459 (44.1) 642 (49.5)
Ex-smoker 317 (30.5) 330 (25.4)
Current smoker 264 (25.4) 326 (25.1)
Own social class
Non-manual 608 (58.5) 1000 (77.0)
Manual 432 (41.5) 298 (23.0)
Father’s social class
Non-manual 328 (31.5) 398 (30.7)
Manual 712 (68.5) 900 (69.3)
142 Gunnell, Whitley, Upton, et al
www.jech.com
 on 13 November 2006 jech.bmj.comDownloaded from 
Associations between anthropometry, FEV1 and
cardiovascular risk factors
Tables 2 and 3 shows the associations of height, leg length,
trunk length, and FEV1 with cardiovascular risk factors. To
facilitate comparison across tables all coefficients represent
the increase (or decrease) in the specified risk factor
associated with a one standard deviation increase in each
measurement. Greater overall height was associated with
reduced total cholesterol and fibrinogen concentrations, non-
manual social class (own and parental), higher FEV1, and birth
weight. In women, but not men, stature was associated with a
lower white blood cell count and BMI.
Leg length, but not trunk length, was inversely associated
with systolic and diastolic blood pressure. Leg length was
more strongly inversely associated with cholesterol levels
than trunk length. Greater trunk length was associated with
a raised body mass index in men, the opposite was seen with
respect to leg length in both sexes. High leg to trunk length
ratios were associated with favourable profiles of blood pres-
sure, BMI, HDL, and total cholesterol in all subjects as well as
lower glucose in men and lower fibrinogen in women.
Current smokers were more likely to have higher leg to trunk
length ratios. Associations with other cardiovascular risk fac-
tors differed little for the two components of stature. Social
Table 2 Age adjusted change in levels of cardiovascular risk factors per standard deviation (SD) increase in (a) height,
(b) leg length, (c) trunk length, (d) leg: trunk ratio and (e) forced expiratory volume in 1 second (FEV1).* (continuous
variables)
(a) Height
(change (95% CI), p
value per SD increase in
height)
(b) Leg length
(change (95% CI), p
value per SD increase in
leg length)
(c) Trunk length
(change (95% CI), p
value per SD increase in
trunk length)
(d) Leg: Trunk ratio
(change (95% CI), p
value per SD increase in
ratio)
(e) FEV1
(change (95% CI), p
value per SD increase in
FEV1)
Systolic blood pressure (mm Hg)
Men −0.50 (−1.44 to 0.44) −1.14 (−2.06 to −0.21) 0.42 (−0.53 to 1.38) −1.48 (−2.41 to –0.54) −1.66 (−2.75 to −0.57)
p=0.29 p=0.02 p=0.39 p=0.002 p=0.003
Women −0.68 (−1.53 to 0.17) −1.09 (−1.93 to −0.25) 0.08 (−0.79 to 0.95) −1.17 (−2.02 to –0.32) −1.81 (−2.77 to −0.85)
p=0.12 p=0.01 p=0.86 p=0.01 p<0.001
Diastolic blood pressure (mm Hg)
Men −0.25 (−0.93 to 0.44) −0.87 (−1.56 to −0.18) 0.60 (−0.06 to 1.27) −1.32 (−1.98 to –0.67) −1.11 (−1.82 to −0.39)
p=0.48 p=0.01 p=0.07 p=0.02 p=0.002
Women −0.18 (−0.76 to 0.41) −0.49 (−1.06 to 0.08) 0.28 (−0.31 to 0.87) −0.71 (−1.27 to –0.15) −0.53 (−1.15 to 0.10)
p=0.55 p=0.09 p=0.35 p=0.01 p=0.10
Total cholesterol (mmo1/1)
Men −0.13 (−0.19 to −0.07) −0.12 (−0.18 to −0.07) −0.09 (−0.15 to −0.02) −0.06 (−0.12 to 0.00) −0.10 (−0.17 to −0.04)
p<0.001 p<0.001 p=0.01 p=0.07 p=0.001
Women −0.10 (−0.16 to −0.05) −0.11 (−0.16 to −0.06) −0.06 (−0.11 to −0.01) −0.07 (−0.12 to 0.02) −0.12 (−0.18 to −0.06)
p<0.001 p<0.001 p=0.02 p=0.01 p<0.001
High density lipoprotein cholesterol (mmo1/1)
Men 0.00 (−0.02 to 0.02) 0.02 (−0.01 to 0.04) −0.02 (−0.04 to 0.01) 0.03 (0.00 to 0.05) 0.01 (−0.01 to 0.04)
p=0.95 p=0.18 p=0.17 p=0.02 p=0.31
Women −0.00 (−0.02 to 0.02) 0.01 (−0.01 to 0.04) −0.02 (−0.04 to 0.00) 0.01 (0.00 to 0.05) 0.02 (−0.02 to 0.03)
p=0.96 p=0.24 p=0.09 p=0.02 p=0.47
Random glucose (mmo1/1)
Men −0.05 (−0.17 to 0.07) −0.10 (−0.22 to 0.03) 0.03 (−0.09 to 0.15) −0.11 (−0.23 to 0.00) −0.22 (−0.37 to −0.07)
p=0.43 p=0.13 p=0.65 p=0.06 p=0.01
Women −0.01 (−0.07 to 0.05) −0.01 (−0.06 to 0.05) −0.01 (−0.08 to 0.06) 0.00 (−0.07 to 0.07) −0.06 (−0.12 to 0.01)
p=0.73 p=0.79 p=0.85 p=0.95 p=0.09
Fibrinogen (g/l)
Men −0.09 (−0.13 to −0.04) −0.05 (−0.10 to −0.01) −0.09 (−0.14 to −0.03) 0.01 (−0.04 to 0.07) −0.17 (−0.22 to −0.11)
p<0.001 p=0.02 p=0.002 p=0.61 p<0.001
Women −0.06 (−0.10 to −0.02) −0.07 (−0.12 to −0.03) −0.02 (−0.07 to 0.02) −0.06 (−0.10 to –0.01) −0.13 (−0.18 to −0.09)
p=0.01 p=0.001 p=0.34 p=0.01 p<0.001
White blood cell count (10−9/1)
Men 0.04 (−0.09 to 0.13) 0.06 (−0.06 to 0.18) −0.03 (−0.14 to 0.08) 0.08 (−0.04 to 0.20) −0.11 (−0.23 to 0.01)
p=0.72 p=0.33 p=0.61 p=0.20 p=0.06
Women −0.14 (−0.25 to −0.04) −0.04 (−0.15 to 0.07) −0.21 (−0.31 to −0.10) 0.11 (−0.01 to 0.22) −0.27 (−0.39 to −0.15)
p=0.01 p=0.46 p<0.001 p=0.06 p<0.001
Forced expiratory volume in 1 second (1)
Men 0.28 (0.24 to 0.32) 0.22 (0.19 to 0.26) 0.24 (0.20 to 0.28) 0.04 (0.00 to 0.09) –
p<0.001 p<0.001 p<0.001 p=0.04
Women 0.20 (0.18 to 0.22) 0.15 (0.13 to 0.18) 0.18 (0.16 to 0.21) 0.02 (−0.01 to 0.05) –
p<0.001 p<0.001 p<0.001 p=0.13
Forced vital capacity (1)
Men 0.43 (0.38 to 0.47) 0.35 (0.30 to 0.39) 0.35 (0.30 to 0.40) 0.09 (0.05 to 0.14) –
p<0.001 p<0.001 p<0.001 p<0.001
Women 0.30 (0.27 to 0.33) 0.24 (0.21 to 0.27) 0.26 (0.23 to 0.28) 0.05 (0.02 to 0.08) –
p<0.001 p<0.001 p<0.001 p=0.001
Recorded birth weight (kg)
Men 0.12 (0.07 to 0.17) 0.12 (0.06 to 0.17) 0.09 (0.04 to 0.14) 0.05 (−0.01 to 0.11) 0.09 (0.03 to 0.14)
p<0.001 p<0.001 p=0.001 p=0.08 p=0.002
Women 0.13 (0.08 to 0.17) 0.11 (0.05 to 0.16) 0.12 (0.06 to 0.17) 0.02 (−0.04 to 0.08) 0.10 (0.04 to 0.16)
p<0.001 p<0.001 p<0.001 p=0.50 p=0.001
Body mass index
Men −0.10 (−0.37 to 0.18) −0.59 (−0.87 to −0.31) 0.52 (0.24 to 0.80) −0.95 (−1.22 to –0.68) −0.40 (−0.73 to −0.08)
p=0.48 p<0.001 p<0.001 p<0.001 p=0.01
Women −0.54 (−0.81 to −0.26) −0.89 (−1.15 to −0.62) 0.08 (−0.19 to 0.36) −0.97 (−1.24 to –0.70) −0.45 (−0.78 to −0.12)
p<0.001 p<0.001 p=0.55 p<0.001 p=0.01
*All confidence intervals are adjusted for intra-family clustering.
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class differences for leg length were similar to those for trunk
length. In a separate analysis, based on the 677 subjects with
recorded birthweight data, we repeated the analysis of leg
length-risk factor associations, controlling for birth weight
(data not shown). There was no evidence that birth weight
confounded associations between leg length and cholesterol,
fibrinogen or body mass index however the inverse associa-
tions of leg length with blood pressure was attenuated.
FEV1 was more strongly associated with systolic blood
pressure, fibrinogen, and white cell count than was height, leg
length, trunk length or leg:trunk ratio. Unlike height, FEV1 was
associated with reduced random glucose andwasmore strongly
Table 3 Age adjusted change in odds ratio of cardiovascular risk factors per standard deviation (SD) increase in (a)
height, (b) leg length, (c) trunk length, (d) leg:trunk ratio and (e) forced expiratory volume in 1 second (FEV 1)*
(categorical variables)
(a) Height
(change (95% CI), p
value per SD increase
in height)
(b) Leg length
(change (95% CI), p
value per SD increase
in leg length)
(c) Trunk length
(change (95% CI), p
value per SD increase
in trunk length)
(d) Leg: trunk ratio
(change (95% CI), p
value per SD increase
in ratio)
(e) FEV1
(change (95% CI), p




Never/ex smoker 1.00 1.00 1.00 1.00 1.00
Current smoker 0.86 (0.74 to 0.99) 1.00 (0.87 to 1.16) 0.76 (0.66 to 0.87) 1.23 (1.06 to 1.42) 0.62 (0.52 to 0.74)
p=0.04 p=0.96 p<0.001 p=0.01 p<0.001
Women
Never/ex smoker 1.00 1.00 1.00 1.00 1.00
Current smoker 1.03 (0.91 to 1.18) 1.10 (0.96 to 1.25) 0.95 (0.84 to 1.08) 1.14 (1.00 to 1.30) 0.58 (0.50 to 0.68)
p=0.63 p=0.18 p=0.44 p=0.05 p<0.001
Own social class
Men
Non-manual 1.00 1.00 1.00 1.00 1.00
Manual 0.72 (0.63 to 0.82) 0.80 (0.71 to 0.91) 0.71 (0.61 to 0.81) 1.04 (0.91 to 1.19) 0.71 (0.62 to 0.83)
p<0.001 p=0.001 p<0.001 p=0.56 p<0.001
Women
Non-manual 1.00 1.00 1.00 1.00 1.00
Manual 0.82 (0.72 to 0.95) 0.84 (0.73 to 0.96) 0.87 (0.76 to 0.99) 0.93 (0.81 to 1.06) 0.78 (0.67 to 0.91)
p=0.01 p=0.01 p=0.04 p=0.28 p=0.001
Father’s social class
Men
Non-manual 1.00 1.00 1.00 1.00 1.00
Manual 0.84 (0.72 to 0.97) 0.89 (0.77 to 1.02) 0.84 (0.72 to 0.97) 1.01 (0.88 to 1.16) 0.74 (0.63 to 0.87)
p=0.02 p=0.10 p=0.02 p=0.89 p<0.001
Women
Non-manual 1.00 1.00 1.00 1.00 1.00
Manual 0.83 (0.73 to 0.94) 0.83 (0.73 to 0.95) 0.88 (0.77 to 1.00) 0.91 (0.79 to 1.04) 0.77 (0.66 to 0.88)
p=0.003 p=0.01 p=0.05 p=0.15 p<0.001
*All confidence intervals are adjusted for intra-family clustering.
Table 4 Age adjusted change in levels of cardiovascular risk factors per standard deviation (SD) increase in own
height adjusted for mid-parental height*
Men Women
Increase (95% CI) p Value Increase (95% CI) p Value
Systolic blood pressure (mm Hg) −0.97 (−2.17 to 0.23) 0.11 −0.78 (−1.86 to 0.31) 0.16
Diastolic blood pressure (mm Hg) −0.34 (−1.18 to 0.50) 0.42 −0.10 (−0.78 to 0.59) 0.78
Total cholesterol (mmol/l) −0.12 (−0.20 to −0.04) 0.002 −0.10 (−0.16 to −0.04) 0.001
High density lipoprotein cholesterol (mmol/l) −0.01 (−0.03 to 0.02) 0.66 −0.08 (−0.04 to 0.02) 0.59
Random glucose (mmol/l) −0.03 (−0.17 to 0.11) 0.68 0.01 (−0.08 to 0.09) 0.88
Fibrinogen (g/l) −0.07 (0.13 to −0.01) 0.02 −0.05 (−0.11 to 0.00) 0.05
White blood cell count (109/l) 0.05 (−0.10 to 0.19) 0.55 −0.20 (−0.33 to −0.06) 0.004
Forced expiratory volume in 1 second (l) 0.26 (0.22 to 0.31) <0.001 0.21 (0.18 to 0.24) <0.001
Forced vital capacity (l) 0.41 (0.35 to 0.46) <0.001 0.30 (0.26 to 0.33) <0.001
Recorded birth weight (kg) 0.13 (0.06 to 0.20) <0.001 0.14 (0.08 to 0.21) <0.001
Body mass index (kg/m2) 0.08 (−0.26 to 0.42) 0.63 −0.61 (−0.96 to −0.27) 0.001
OR (95% CI) p Value OR (95% CI) p Value
Cigarette smoking status
Never/ex smoker 1.00 1.00
Current smoker 0.91 (0.76 to 1.09) 0.32 0.99 (0.84 to 1.16) 0.86
Own social class
Non-manual 1.00 1.00
Manual 0.73 (0.62 to 0.87) <0.001 0.86 (0.72 to 1.02) 0.08
Father’s social class
Non-manual 1.00 1.00
Manual 1.19 (0.99 to 1.42) 0.06 1.03 (0.89 to 1.20) 0.69
*All confidence intervals are adjusted for intra-family clustering.
144 Gunnell, Whitley, Upton, et al
www.jech.com
 on 13 November 2006 jech.bmj.comDownloaded from 
associated with smoking. Associations with FEV1 were essen-
tially unchanged in models controlling for the possible
confounding effects of physical activity (results not shown).
Effects of parental height on offspring’s
height-cardiovascular risk factor association
Controlling for mid-parental height had little effect on the
associations between height and cardiovascular risk profile in
their offspring (table 4). The association between stature and
father’s social class was, however, abolished in these models.
This indicates that parental stature may act as a marker of
parental socioeconomic position as well a marker of geneti-
cally determined height potential.
In separate models we assessed the effects of controlling for
maternal and paternal height separately. Our findings were
similar to those seen in models controlling for mid-parental
height (see above, data not shown).
DISCUSSION
Main findings
This analysis suggests that taller men and women have more
favourable cardiovascular risk profiles than shorter people.
FEV1 is more strongly associated than is height with the
cardiovascular risk factors examined, suggesting it may be a
better biomarker for the factors underlying associations
between pre-adult exposures and adult cardiovascular
disease.17 Associations with stature were largely unchanged in
models controlling for parental height, indicating genetic fac-
tors may not underlie the observed height-risk factor associa-
tions. Furthermore, analysis of the subset of study members
with birthweight data suggests that some stature-
cardiovascular risk factor associations are independent of pre-
natal influences.
Three important risk factors for CHD—raised blood
pressure, BMI and, to a lesser extent, cholesterol—were more
strongly associated with leg length than trunk length. Our
findings for cholesterol and, to a lesser degree, blood pressure
are consistent with those in our analysis of the Caerphilly
cohort; in that analysis adverse patterns of insulin resistance
and fibrinogen were also more strongly related to short leg
length.15 In Midspan study members blood glucose levels were
lower in men with higher leg: trunk ratios.
Unlike previous analyses,15 23–25 we found no evidence that
social class differences in height were in greater part attribut-
able to leg length than trunk length. The associations of FEV1
with leg length were slightly weaker than their relation with
trunk length but were stronger than those we found reported
in Caerphilly where we used a height adjusted measure of
lung function.15 In the analyses reported here we used raw
FEV1 as we were interested in an absolute measure of lung
development rather than lung function in relation to size.
Strengths and limitations
One of the main strengths of this study is the availability of
detailed anthropometry (including sitting height) and lung
function tests. Furthermore, the availability of parental height
measurements enable an assessment of the importance of
genetic influences in the height-CHD risk factor associations.
There are two main limitations to this analysis. Firstly, only
2338 (48%) of the offspring identified took part in the study.
The main reason for non-participation was that these
individuals had moved away from the Paisley and Renfrew
area and so were not invited to take part (the response rate
was 73% in those invited). We have no reason to believe that
exposure-risk factor associations are likely to be different in
the individuals examined compared with those who were not.
In support of this suggestion, FEV1-mortality associations are
similar in the parents whose offspring participated in the
study and those among parents whose offspring did not
(Upton M, manuscript in preparation). Secondly, we had lim-
ited information on birth weight (29% of subjects only) and so
were unable to fully assess its impact on observed associations
in the full dataset. As previously reported,26 associations of
birth weight with leg length and trunk length were similar,
suggesting birth weight is unlikely to confound the observed
differential associations with leg length. However, there was
some evidence that birth weight confounded the associations
of leg length with blood pressure.
Early life and childhood influences on the development
of CHD
The aetiology of CHD is complex and involves several
pathological processes. The importance of development in
utero and in infancy is indicated by associations of both low
birth weight and weight at 1 year with a high risk of CHD.27–29
The role of exposures in the first two decades of life in CHD
development is supported by postmortem studies that reveal
that around 50% of young men have some evidence of athero-
sclerosis (fatty streaks or plaques) in their coronary vessels.30
Blood pressure, blood lipids, body mass index, and smoking in
childhood predict the extent of such postmortem atheroscle-
rotic changes.31 Just as birth weight is used as a biomarker for
in utero exposures, our findings suggest that height and FEV1
may be used as biomarkers for a range of exposures influenc-
ing post-natal growth such as diet, exposure to infection, and
stress.12 17 These factors in turn may have long term influences
on the risk of developing atherosclerosis as indicated by
height-CHD associations.1–6 15 The distinct importance of
childhood exposures, over and above those acting in utero, is
supported by findings in two prospective studies where
adjustment for birth weight did not greatly influence observed
height-CHD associations.2 3 While adult height is a marker for
exposures influencing growth throughout childhood, leg
length seems to be a marker for factors acting in the
pre-pubertal period. Recent studies indicate that longer leg
length is associated with breast feeding, energy rich diets at
age 2 and affluent social circumstances.25 24 32 Thus analyses
reporting that leg length is the component of height most
strongly related to later risk of CHD7 15 indicate that one (or
more) of these exposures pre-pubertally may be important in
generating CHD risk.
FEV1 and cardiovascular disease
Findings from the few studies33–36 that have examined associa-
tions between lung function and cardiovascular risk factor
levels are broadly consistent with those reported in this paper.
In the Paisley and Renfrew cohort, which includes the parents
of subjects forming the basis of our analyses, higher FEV1 was
associated with lower body mass index and cholesterol levels
in men and women but there was no association with diasto-
lic blood pressure.33 Associations between FEV1 and CHD mor-
tality in the Paisley and Renfrew cohort were independent of
Key points
• Taller people and those with good lung function (FEV1) are
at reduced risk of coronary heart disease (CHD).
• Leg length, an indicator of pre-pubertal nutritional status,
seems to be the component of height most strongly associ-
ated with risk.
• In a study of 2338 men and women aged 30–59 we found
that taller people and those with better lung function had
more favourable cardiovascular risk factor profiles.
Associations were strongest with lung function.
• Height (particularly leg length) and FEV1 may both be
markers for childhood exposures which influence growth
and CHD risk.
• Genetic influences do not seem to underlie height-CHD risk
factor associations.
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other coronary risk factors including smoking, cholesterol,
diastolic blood pressure, body mass index, and social class.33 In
Framingham, vital capacity was inversely associated with
diastolic blood pressure, but associations with blood sugar and
cholesterol differed in different age and sex groups.35 In the
Gothenburg cohort of middle age women, cholesterol and
triglycerides levels decreased with increases in peak expira-
tory flow rates.34
While previous research indicates that FEV1 seems to be a
more powerful predictor of CHD risk than height, height has
two main advantages over FEV1 as an epidemiological biomar-
ker for early life exposures. Firstly, it is straightforward to
measure accurately and is also self reported with reasonable
precision. Secondly, with the exception of age related changes,
it is little influenced by exposures subsequent to growth
cessation. In contrast FEV1 may be affected by smoking—itself
a powerful predictor of CHD risk.
What this study contributes to an understanding of
childhood influences on CHD
This analysis provides some support for the importance of
childhood exposures in generating height-CHD associations.
We have reported four main findings. Firstly, we have found
associations between a range of well recognised cardiovascular
risk factors and both height and FEV1. Secondly, stature-risk
factor associations are generally stronger for leg length than
trunk length. This hints at the importance of pre-pubertal
exposures, in generating height-CHD associations. Thirdly,
controlling for parental stature had little effect on height-risk
factor associations. This suggests that genetic factors may not
underlie associations between height and cardiovascular risk
factor profiles. Lastly, we found that FEV1 was more strongly
associated with cardiovascular risk factor profiles than the
anthropometric measures. If FEV1 is acting as a biomarker for
childhood exposures in the FEV1-cardiovascular risk profile
associations, then this finding suggests it is a more sensitive
measure of the childhood exposures, such as diet and
socioeconomic circumstances, that lead to the development of
CHD than is childhood stature.
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